WTW Survey: Fewer US Employers to Cover GLP-1 Weight-Loss Drugs in 2026

The first coverage decline since these drugs went mainstream marks a shift from expansion to retrenchment in employer-sponsored benefits, and the fact that nearly a third of remaining coverers are weighing an exit suggests the drop may not be a one-off. This matters most for employees who have built weight-loss treatment around plan coverage, and for the drugmakers whose growth case has leaned on broad commercial access. Whether the pullback spreads beyond large self-insured plans, and how plan design changes—rather than outright drops—absorb the cost pressure, is the open question to watch.